Home - Chinese Journal of Cancer Research

2020 Impact Factor of CJCR: 5.087
Journal Citation Reports®, Clarivate Analytics

National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version)

National Health Commission of the People’s Republic of China

Cancer burden and trends in China: A review and comparison with Japan and South Korea

Cancer is the leading cause of death worldwide. Distinct geographic disparities exist in cancer burden across the world. China, Japan, and South Korea are all located in East Asia. As neighboring countries, Japan and South Korea share similar genetic backgrounds and similar culture with China. Also, in terms of cancer burden, these three countries are all facing a heavy burden of upper digestive tract cancers. This article provides an overview of cancer burden and trends in China by comparing with Japan and South Korea. Comparison among these three countries for the cancer burden and trends could be useful to track the effectiveness of national screening programs and to identify modifiable risk factors. The results can serve as a scientific reference for cancer control policy planning.

Cancer incidence and mortality in China, 2014

In 2017, National Central Cancer Registry of China (NCCRC) updated nationwide cancer statistics using population-based cancer registry data in 2014 collected from all available cancer registries. There are 449 cancer registries submitted cancer registry data in 2014, among which 339 registries’ data met the criteria of quality control and were included in analysis. These cancer registries covered 288,243,347 population, accounting for about 21.07% of the national population in 2014. Numbers of nationwide new cancer cases and deaths were estimated using calculated incidence and mortality rates and corresponding national population stratified by area, sex, age group and cancer type. The world Segi’s population was applied for age-standardized rates. Heavy cancer burden and its disparities between area, sex and age group pose a major challenge to public health in China. Nationwide cancer registry plays a crucial role in cancer prevention and control.

Cancer incidence in Beijing, 2014

To analyze cancer incidence data in Beijing in 2014 and temporal trends for selected common cancers during 2005 and 2014. A total of 144 secondary and tertiary hospitals reported newly diagnosed cancer cases to Beijing Cancer Registry, which covers 13 million residents in Beijing. The cancer incidence rate was calculated in strata by cancer type, sex, age group and area. The population composition of China in 1982 and Segi’s population structure were used to calculate age-standardized rates. Extensive procedures were used to assure the quality of the data. A total of 45,300 new cancer cases were diagnosed in Beijing in 2014. The incidence rate was 341.92/100,000 (343.50/100,000 in males, 340.33/100,000 in females). Cancer remains an important public health problem. Actions should be taken to diminish total cancer incidence in Beijing.

‹ ›

Vol 33, No 3 (June 2021)

Guidelines

CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Zhijun Yuan, Shanshan Weng, Chenyang Ye, Hanguang Hu, Suzhan Zhang, Ying Yuan

Pages: 67-70 HTML

Original Article

Prognostic and incremental value of computed tomography-based radiomics from tumor and nodal regions in esophageal squamous cell carcinoma

Bangrong Cao, Kun Mi, Wei Dai, Tong Liu, Tianpeng Xie, Qiang Li, Jinyi Lang, Yongtao Han, Lin Peng, Qifeng Wang

Pages: 71-82 HTML

Genomic landscape of T-cell lymphoblastic lymphoma

Zhaoming Li, Yue Song, Mingzhi Zhang, Yiming Wei, Hang Ruan

Pages: 83-94 HTML

Establishment of an optimized CTC detection model consisting of EpCAM, MUC1 and WT1 in epithelial ovarian cancer and its correlation with clinical characteristics

Tongxia Wang, Yan Gao, Xi Wang, Junrui Tian, Yuan Li, Bo Yu, Cuiyu Huang, Hui Li, Huamao Liang, David M. Irwin, Huanran Tan, Hongyan Guo

Pages: 95-108 HTML

Perspective

Current status and perspectives of conversion therapy for advanced gastric cancer

Heli Yang, Ke Ji, Jiafu Ji

Pages: 109-114 HTML

Commentary

Pan-cancer tumor-infiltrating T cells: A great hallmark in cancer immunology research

Anqiang Wang, Zhaode Bu

Pages: 115-116 HTML

Review Article

Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer

Yuehua Liang, Xiaoran Liu, Kun Li, Huiping Li

Pages: 117-130 HTML

CSCO Guidelines

Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020

Caixia Dong, Yuwei Ding, Shanshan Weng, Guichao Li, Yanqing Huang, Hanguang Hu, Zhen Zhang, Suzhan Zhang, Ying Yuan

Pages: 302-307 HTML

Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019

Shanshan Weng, Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 403-407 HTML

Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018

Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 423-425 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer working group

Pages: 84-98 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer working group

Pages: 99-116 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer working group

Pages: 117-134 HTML

Guidelines

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Jun Zhu, Jun Ma, Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology

Pages: 289-301 HTML

Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor

Jian Li, Yingjiang Ye, Jian Wang, Bo Zhang, Shukui Qin, Yingqiang Shi, Yulong He, Xiaobo Liang, Xiufeng Liu, Ye Zhou, Xin Wu, Xinhua Zhang, Ming Wang, Zhidong Gao, Tianlong Lin, Hui Cao, Lin Shen, Chinese Society of Clinical Oncology (CSCO) Expert Committee on Gastrointestinal Stromal Tumor

2020 Impact Factor of CJCR: 5.087Journal Citation Reports®, Clarivate Analytics

National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version)

Cancer burden and trends in China: A review and comparison with Japan and South Korea

Cancer incidence and mortality in China, 2014

Cancer incidence in Beijing, 2014

About cjcr

Advertising

Contact us

Guidelines

Original Article

Perspective

Commentary

Review Article

CSCO Guidelines

Guidelines

NHCPRC Guidelines

Virtual Special Issues

Beijing Cancer Hospital

China Anti-cancer Association

Chronic Diseases and Translational Medicine

2018 CGCC

2020 Impact Factor of CJCR: 5.087
Journal Citation Reports®, Clarivate Analytics